Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,688,810
  • Shares Outstanding, K 58,275
  • Annual Sales, $ 60,000 K
  • Annual Income, $ -78,960 K
  • 60-Month Beta 2.05
  • Price/Sales 27.53
  • Price/Cash Flow N/A
  • Price/Book 4.86
Trade PTGX with:

Options Overview Details

View History
  • Implied Volatility 60.77% ( +0.34%)
  • Historical Volatility 44.19%
  • IV Percentile 24%
  • IV Rank 25.93%
  • IV High 125.30% on 09/19/23
  • IV Low 38.18% on 03/11/24
  • Put/Call Vol Ratio 0.31
  • Today's Volume 17
  • Volume Avg (30-Day) 91
  • Put/Call OI Ratio 2.16
  • Today's Open Interest 2,738
  • Open Int (30-Day) 3,114

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 2.51
  • Number of Estimates 3
  • High Estimate 4.33
  • Low Estimate -0.55
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +474.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.32 +8.13%
on 02/21/24
33.34 -14.64%
on 03/01/24
+0.41 (+1.46%)
since 02/16/24
3-Month
20.71 +37.42%
on 12/20/23
33.34 -14.64%
on 03/01/24
+7.73 (+37.29%)
since 12/18/23
52-Week
13.72 +107.43%
on 10/25/23
33.34 -14.64%
on 03/01/24
+6.04 (+26.94%)
since 03/17/23

Most Recent Stories

More News
Protagonist Therapeutics: Q4 Earnings Snapshot

Protagonist Therapeutics: Q4 Earnings Snapshot

PTGX : 28.46 (-1.79%)
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

NVS : 95.92 (-1.39%)
JNJ : 156.76 (-0.90%)
LEGN : 64.66 (+1.00%)
CVRX : 20.65 (-0.82%)
PTGX : 28.46 (-1.79%)
Protagonist Therapeutics: Q3 Earnings Snapshot

Protagonist Therapeutics: Q3 Earnings Snapshot

PTGX : 28.46 (-1.79%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling...

RY : 99.27 (-0.07%)
RY.TO : 134.34 (-0.22%)
ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
JAZZ : 123.41 (+2.08%)
ZYME : 10.71 (-0.93%)
AMGN : 270.90 (+0.76%)
PTGX : 28.46 (-1.79%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

/PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer...

ONC.TO : 1.42 (+5.97%)
ONCY : 1.0400 (+5.17%)
ZYME : 10.71 (-0.93%)
JAZZ : 123.41 (+2.08%)
PTGX : 28.46 (-1.79%)
AMGN : 270.90 (+0.76%)
Pioneering Cancer Treatments Show Promising Progress Despite Fiscal Challenges

USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer...

RY : 99.27 (-0.07%)
RY.TO : 134.34 (-0.22%)
ONCY : 1.0400 (+5.17%)
ONC.TO : 1.42 (+5.97%)
JAZZ : 123.41 (+2.08%)
ZYME : 10.71 (-0.93%)
AMGN : 270.90 (+0.76%)
PTGX : 28.46 (-1.79%)
Protagonist Therapeutics: Q2 Earnings Snapshot

Protagonist Therapeutics: Q2 Earnings Snapshot

PTGX : 28.46 (-1.79%)
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?

With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.

BMEA : 15.77 (-11.68%)
SPPI : 1.0300 (unch)
PTGX : 28.46 (-1.79%)
Chart of the Day: Protagonist Therapeutics - Wide Opinions

The Chart of the Day belongs to the biopharmaceutical company Protagonist Therapeutics (PTGX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

PTGX : 28.46 (-1.79%)
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported data from its collaboration with Janssen Biotech, Inc., one...

PTGX : 28.46 (-1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 30.01
2nd Resistance Point 29.61
1st Resistance Point 29.04
Last Price 28.46
1st Support Level 28.07
2nd Support Level 27.67
3rd Support Level 27.10

See More

52-Week High 33.34
Last Price 28.46
Fibonacci 61.8% 25.85
Fibonacci 50% 23.53
Fibonacci 38.2% 21.21
52-Week Low 13.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar